BRAIN Graphic
Investors

BRAIN Biotech is a key player in the bio-based economy

BRAIN Biotech AG ranks among the technologically leading companies in Europe in the bioeconomy area, and operates in industrial biotechnology with its key technologies.

BRAIN Biotech identifies previously untapped high-performing enzymes, microbial producer organisms and natural compounds derived from complex biological systems to transform them into industrially usable applications.

Innovative solutions and products developed from this Toolbox of Nature are successfully deployed in the chemicals sector, as well as in the cosmetics and food manufacturing industries.

As part of its growth-oriented industrialization strategy, BRAIN Biotech AG (ISIN DE0005203947 / WKN 520394) has been the first bioeconomy company to be listed in the Prime Standard of the Frankfurt Stock Exchange since February 2016.

BRAIN-engineered-Cas – Elevator pitch

9M-Update – FY 2021/22

IR Contact BRAIN AG

Investor Relations

Selected publications and financial events


Financial Publication

Quarterly Statement as of 30 June 2022

BRAIN Biotech AG, 29 August 2022

Download PDF

Next Financial Event

Publication of the annual report as at 30.09.2022 (12M)

16 January 2023
Financial Calendar

Recent financial news


Corporate News, 29 August 2022

BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting

Show news

Corporate News, 20 June 2022

BRAIN Biotech publishes first ESG and Sustainability Report

Show news

Corporate News, 30 May 2022

BRAIN Biotech AG: Prof. Dr. Bernhard Hauer leaves Supervisory Board of BRAIN Biotech AG for personal reasons

Show news

Investor Relations service

You want to invest in BRAIN Biotech AG or have questions? We are here for you. Please get in touch with us.

Contact Investor Relations

Good reasons to invest in BRAIN Biotech AG

We address important social topics

We address some of the big social issues: better, healthier and more sustainable living.

We serve the concept of bioeconomy

Our products and solutions directly address the sustainability goals of the United Nations: 2, 3, 6, 9, and 12.
Among other things, we aim to replace petrochemical processes by biotechnological processes, based on our proprietary resource collection, the BRAIN BioArchive.

Solutions
Products for diverse industrial applications

Our innovative solutions (Tailor-made-solutions, TMS) as well as our products business show a low correlation with economic cycles and enable structural growth.

Products & Markets
Broad and in-depth technology expertise

We have a broad and profound technological expertise in enzymes, microorganisms, cell-based testing methods and natural products. Combined with our collection of natural resources, the BRAIN BioArchive, we develop disruptive new biobased products and solutions.

Reliable R&D partner

In more than 100 successfully completed R&D partnerships (Tailor made Solutions, TMS) we have proven our competence and reliability.

Services
Markets with high entry barriers

Our proprietary BRAIN BioArchive, an extensive patent portfolio, our broad and in-depth technology know-how as well as our first class scientists build high barriers to market entry.

BRAIN Group

Share this page